Journal of Nanomedicine & Biotherapeutic Discovery
Open Access

Sylvia Wagner

Publications

• Research Article
  Flurbiprofen-loaded Nanoparticles Can Cross a Primary Porcine In vitro Blood-brain Barrier Model to Reduce Amyloid-β 42 Burden
  Author(s): Julia Stab, Iavor Zlatev, Bastian Raudszus, Sabrina Meister, Claus U Pietrzik, Klaus Langer, Hagen von Briesen and Sylvia Wagner Julia Stab, Iavor Zlatev, Bastian Raudszus, Sabrina Meister, Claus U Pietrzik, Klaus Langer, Hagen von Briesen and Sylvia Wagner
  
  Elevated amyloid-β42 (Aβ42) in the brain is expected to cause Alzheimer’s Disease (AD). Reducing Aβ42 is therefore a cornerstone in causal drug development. Nevertheless, many promising substances failed in clinical trials, because reaching the target organ in vivo is difficult. The brain is protected by the Blood-Brain Barrier (BBB) that shields off most molecules to maintain the brain homeostasis. Brain-targeted nanoparticles are one successful tool to bypass this problem: by acting as Trojan horses they carry embedded drugs across the BBB for brain disorder treatment. Here, flurbiprofen, a γ-secretase modulator, was embedded in Poly(Lactic Acid) (PLA) nanoparticles. We tested if the drug-loaded nanoparticles affected the integrity of our advanced in vitro BBB model in transendothelial electrical resistance measurements and permeability.. View More»
  DOI: 10.4172/2155-983X.1000140

  Abstract PDF

Relevant Topics